ZBH

Zimmer Biomet Holdings Inc

Add to Watchlist

Advanced Chart

91.650

-1.67(-1.790%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

93.200

Open

92.060

VWAP

91.94

Vol

1.80M

Mkt Cap

18.13B

Low

91.560

Amount

165.65M

EV/EBITDA(TTM)

9.63

Total Shares

205.73M

24.26B

EV/OCF(TTM)

14.67

P/S(TTM)

2.45

Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; biologics, sports medicine, extremities and trauma (S.E.T.) products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and ankle, among others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

2.06B

+5.85%

1.976

-1.69%

1.99B

+9.29%

1.835

+5.47%

2.22B

+9.68%

2.350

+1.74%

Estimates Revision

The market is revising Upward the revenue expectations for Zimmer Biomet Holdings, Inc. (ZBH) for FY2025, with the revenue forecasts being adjusted by 1.82% over the past three months. During the same period, the stock price has changed by -9.99%.

Revenue Estimates for FY2025

Revise Upward

+1.82%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.08%

In Past 3 Month

Stock Price

Go Down

-9.99%

In Past 3 Month

21 Analyst Rating

18.12% Upside

Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 108.26 USD with a low forecast of 95.00 USD and a high forecast of 135.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

11 Hold

2 Sell

Moderate Buy

18.12% Upside

Current: 91.650

Low

95.00

Averages

108.26

High

135.00

18.12% Upside

Current: 91.650

Low

95.00

Averages

108.26

High

135.00

Roth Capital

Roth

Neutral -> Buy

upgrade

$115 -> $135

2025-07-15

Reason

Roth Capital

Roth

Price Target

$115 -> $135

2025-07-15

upgrade

Neutral -> Buy

Reason

Roth Capital upgraded Zimmer Biomet (ZBH) to Buy from Neutral with a price target of $135, up from $115. The firm notes that the announcement of the acquisition of Monogram Technologies (MGRM) covers a critical technological deficit within robotics and puts the company's core large joint franchise on the right track and positioned to challenge Stryker's (SYK) dominance in robotics with MAKO. It also follows the recent acquisition of Paragon 28, signaling the company is finally positioned to diversify to higher growth opportunities, much like Stryker began 20 years ago to great success, Roth adds.

Canaccord

Hold

downgrade

$115 -> $101

2025-05-12

Reason

Canaccord

Price Target

$115 -> $101

2025-05-12

downgrade

Hold

Reason

Canaccord lowered the firm's price target on Zimmer Biomet to $101 from $115 and keeps a Hold rating on the shares. The firm updated its model where they lowered their EPS estimates with the P28 acquisition and efforts to fall more in line with the current stock price post earnings with a slightly higher applied discount to the comp group.

Truist Securities

Richard Newitter

Hold

Reiterates

$118 → $113

2025-02-10

Reason

Truist Securities

Richard Newitter

Price Target

$118 → $113

2025-02-10

Reiterates

Hold

Reason

Barclays

Matt Miksic

Sell

Maintains

$118 → $112

2025-02-10

Reason

Barclays

Matt Miksic

Price Target

$118 → $112

2025-02-10

Maintains

Sell

Reason

Barclays lowered the firm's price target on Zimmer Biomet to $112 from $118 and keeps an Underweight rating on the shares. The firm updated its projections to be in-line with Zimmer's 2025 outlook.

RBC Capital

Shagun Singh

Buy

Maintains

$130 → $125

2025-02-07

Reason

RBC Capital

Shagun Singh

Price Target

$130 → $125

2025-02-07

Maintains

Buy

Reason

Raymond James

Jayson Bedford

Buy

Maintains

$126 → $119

2025-02-07

Reason

Raymond James

Jayson Bedford

Price Target

$126 → $119

2025-02-07

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Zimmer Biomet Holdings Inc (ZBH.N) is 11.64, compared to its 5-year average forward P/E of 16.49. For a more detailed relative valuation and DCF analysis to assess Zimmer Biomet Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

16.49

Current PE

11.64

Overvalued PE

19.24

Undervalued PE

13.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

12.66

Current EV/EBITDA

9.10

Overvalued EV/EBITDA

14.58

Undervalued EV/EBITDA

10.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

3.40

Current PS

2.26

Overvalued PS

3.93

Undervalued PS

2.88

Financials

Annual

Quarterly

FY2025Q1

YoY :

+1.05%

1.91B

Total Revenue

FY2025Q1

YoY :

-12.94%

341.00M

Operating Profit

FY2025Q1

YoY :

+5.61%

182.50M

Net Income after Tax

FY2025Q1

YoY :

+8.33%

0.91

EPS - Diluted

FY2025Q1

YoY :

+251.59%

276.00M

Free Cash Flow

FY2025Q1

YoY :

-3.17%

63.29

Gross Profit Margin - %

FY2025Q1

YoY :

+34.30%

14.29

FCF Margin - %

FY2025Q1

YoY :

+4.48%

9.56

Net Margin - %

FY2025Q1

YoY :

-7.84%

5.88

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

95.0K

USD

3-6

Months

150.7K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

93.8K

Volume

6-9

Months

988.3K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

689.7K

Volume

Months

6-9

1.2M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

16.0K

USD

3-6

Months

0.0

USD

6-9

Months

16.0K

USD

0-12

Months

0.0

USD

Bought

0-3

8.0K

USD

Months

3-6

8.0K

USD

Months

6-9

0.0

USD

Months

0-12

16.0K

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

95.0K

USD

3-6

Months

150.7K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ZBH News & Events

Events Timeline

2025-07-14 (ET)

2025-07-14

07:39:29

Zimmer Biomet to acquire Monogram for $4.04 per share in cash upfront

2025-07-14

07:32:34

Zimmer Biomet to acquire Monogram Orthopaedics for $177M

2025-06-05 (ET)

2025-06-05

13:01:25

Treace Medical files patent infringement suit against Zimmer Biomet

News

3.5

07-29Globenewswire

Monogram Technologies Announces World’s First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery

5.0

07-25Yahoo Finance

Wound Debridement Devices Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring B. Braun Melsungen, Essity Aktiebolag, PAUL HARTMANN

9.5

07-25NASDAQ.COM

Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?